Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by stockbuphoonon Nov 11, 2019 6:46pm
114 Views
Post# 30337296

RE:And another loan for 75M

RE:And another loan for 75M

Holy fack, rinse and repeat the cramdown? No chance to get on nasdaq apparently so squish the rest of the Consonance shares and remaining retailers. They prepared the loan docs in April at same time they crammed everyone down. It's clear there is value here and they are screwing the final investors hard before they take it private. Look out below. I think we will see $1 tomorrow and then continue down from there. 


GoBBs wrote:
that apparently they couldn't do in April ?  Wow this looks terrible on Thomtheft...no surprise...
 

  • On November 11, 2019, the Company entered into an amendment to its consolidated loan agreement with the Company's majority shareholder, Structured Alpha LP ("SALP"), to provide the Company with a non-revolving CAD$75,000,000 (the "Principal Amount") line of credit (the "Facility"). The loan agreement between SALP and the Company dated as of April 23, 2019 has been amended to incorporate the terms of the Facility (the "Amended Loan Agreement"). For more information, see Section entitled: About Amended Loan Agreement.


<< Previous
Bullboard Posts
Next >>